Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026GlobeNewsWire · 4 days ago
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · 5 days ago
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?PRNewsWire · Oct 13, 2026
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERNBusiness Wire · Oct 12, 2026
Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and AsiaGlobe News Wire · Oct 12, 2026
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?GuruFocus · Sep 25, 2026Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.01 | -$0.02 | Miss |
| May 6, 2026 | -$0.03 | -$0.01 | Beat |
| Feb 25, 2026 | -$0.03 | -$0.03 | Beat |
| Nov 5, 2025 | -$0.04 | -$0.03 | Beat |
| Aug 6, 2025 | -$0.03 | -$0.02 | Beat |
| May 7, 2025 | -$0.04 | -$0.03 | Beat |